Skip to main content
letter
. 2022 Nov 15;14(7):540–545. doi: 10.1093/procel/pwac052

Figure 2.

Figure 2.

hfCas12Max mediates high-efficiency gene editing ex vivo and in vivo. (A) Schematics of hfCas12Max gene editing in primary human cells. (B) Viability and indel activity of human CD3+ T cells following delivery of hfCas12Max RNPs with three different TRAC targeted crRNAs at 1.6 and 3.2 μmol/L, respectively (n = 2 or 3). NC represents blank control, untreated with RNP. (C) Representative flow cytometric analysis of edited CD3+ T cell 5 days after RNP delivery. NC represents blank control, untreated with RNP. (D) Schematics of in vivo non-liposome delivery containing IVT-mRNA, LNP packaging process. (E) Editing efficiency of LNP packaging with hfCas12Max mRNA and targeted Ttr crRNA at increased concentrations in N2a cells (n = 8). (F) Schematics of Ttr locus. (G) Indel rates of LNP packaging with hfCas12Max mRNA and targeted Ttr crRNA at three dose (0.1, 0.3, and 0.5 mpk) in C57 mouse (n = 6). (H) The A to G editing percentage of LNP packaging with dCas12i-ABE mRNA and targeted Ttr crRNA at 3 mpk in C57 mouse (n = 2).